About this episode

This episode discusses the bleeding risk associated with Apixaban versus Rivaroxaban in the context of the COBRRA trial.

ACCP EM PRN: April 2026 Article: https://pubmed.ncbi.nlm.nih.gov/41812192/ Presenter: Emma Seals | PharmD Candidate 2026 | The Ohio State University College of Pharmacy Copyright Notice: By accessing this podcast, you understand and acknowledge that its contents and materials are the property of ACCP and the Emergency Medicine PRN. Further, the podcast, its contents and its materials are protected under United States and international copyright and trademark law. You understand that the podcast, its contents or materials are to be used only for personal or non-commercial purposes. Limitation of Liability; ACCP AND THE EMERGENCY MEDICINE PRN DISCLAIM ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR ANY OTHER DAMAGES, INCLUDING WITHOUT LIMITATION, LOSS OF PROFITS, ARISING OUT OF ANY USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE THE PODCAST, ITS CONTENTS AND MATERIALS. Produced by Christian Kroll, PharmD, BCPS

People in this episode

Host: Christian Kroll

Guest: Emma Seals

Topics covered

• bleeding risk
• apixaban
• rivaroxaban
• venous thromboembolism
• COBRRA trial
• emergency medicine

Keywords

• bleeding risk
• Apixaban
• Rivaroxaban
• acute venous thromboembolism
• COBRRA trial
• emergency medicine
• pharmacy

Mentioned in this episode

Organizations: The Ohio State University College of Pharmacy, ACCP, Emergency Medicine PRN

Products: Apixaban, Rivaroxaban

More episodes of The Code Tray: The ACCP Emergency Medicine PRN Podcast

• IV Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants​ · May 26, 2026 · 22 min
• Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the ED · May 19, 2026 · 26 min

Explore listener stats, chart rankings, contacts and more on the The Code Tray: The ACCP Emergency Medicine PRN Podcast podcast page.